Testing effectiveness (Phase 2)Ended earlyNCT02443337What this trial is testingLY3023414 and Necitumumab in Squamous Lung CancerWho this might be right forNon-small Cell Lung Cancer Metastatic Eli Lilly and Company 31
Early research (Phase 1)Study completedNCT01976741What this trial is testingDose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)Who this might be right forNeoplasms Bayer 168
Testing effectiveness (Phase 2)Looking for participantsNCT06568939What this trial is testingAssess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-Small Cell Lung Cancer AbbVie 150
Early research (Phase 1)Looking for participantsNCT06022029What this trial is testingA Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.Who this might be right forTriple Negative Breast CancerDiffuse Large B Cell LymphomaFollicular Lymphoma+11 more OncoNano Medicine, Inc. 168
Large-scale testing (Phase 3)UnknownNCT01656551What this trial is testingMILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung CancerWho this might be right forNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IIIB National Cancer Institute, Naples 232
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07742956What this trial is testingPhase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.Who this might be right forNSCLC (Advanced Non-small Cell Lung Cancer) Shanghai Allink Biotherapeutics Co., Ltd. 156
Testing effectiveness (Phase 2)Ended earlyNCT04581824What this trial is testingEfficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)Who this might be right forLung Cancer, Non-Small Cell GlaxoSmithKline 243
Testing effectiveness (Phase 2)Study completedNCT00003103What this trial is testingChemotherapy in Treating Patients With Solid TumorsWho this might be right forBladder CancerBreast CancerColorectal Cancer+7 more Memorial Sloan Kettering Cancer Center 57
Testing effectiveness (Phase 2)Ended earlyNCT02919462What this trial is testingOpen-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase ExpressionWho this might be right forCarcinoma, Non-Small-Cell LungSecondaryAdvanced Stage IIIB+1 more Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 2
Testing effectiveness (Phase 2)Looking for participantsNCT05123482What this trial is testingA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesWho this might be right forBreast CancerBiliary Tract CarcinomaOvarian Cancer+2 more AstraZeneca 460
Early research (Phase 1)Looking for participantsNCT05107674What this trial is testingNX-1607 in Adults With Advanced MalignanciesWho this might be right forOvarian Cancer, EpithelialGastric CancerGastroEsophageal Junction (GEJ) Cancer+11 more Nurix Therapeutics, Inc. 345
Testing effectiveness (Phase 2)Study completedNCT03625323What this trial is testingCombination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCCWho this might be right forNSCLCHNSCC Immutep S.A.S. 187
Early research (Phase 1)Study completedNCT03236935What this trial is testingPhase Ib of L-NMMA and PembrolizumabWho this might be right forNon-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell Carcinoma+3 more The Methodist Hospital Research Institute 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07743723What this trial is testingIOV-5001 in Adults With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsNon-Small Cell Lung CancerTriple Negative Breast Cancer (TNBC)+4 more Iovance Biotherapeutics, Inc. 106
Testing effectiveness (Phase 2)UnknownNCT03706287What this trial is testingEfficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLCWho this might be right forLung Cancer Metastatic Sichuan Cancer Hospital and Research Institute 62
Large-scale testing (Phase 3)Active Not RecruitingNCT06711900What this trial is testingSKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 432
Testing effectiveness (Phase 2)Active Not RecruitingNCT02955290What this trial is testingCIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck CancerWho this might be right forAdvanced Head and Neck Squamous Cell CarcinomaLung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell Carcinoma+13 more Roswell Park Cancer Institute 51
Testing effectiveness (Phase 2)Study completedNCT03789097What this trial is testingVaccination With Flt3L, Radiation, and Poly-ICLCWho this might be right forNon-Hodgkin's LymphomaMetastatic Breast CancerHead and Neck Squamous Cell Carcinoma Icahn School of Medicine at Mount Sinai 17
Large-scale testing (Phase 3)Active Not RecruitingNCT05048797What this trial is testingInvestigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 MutationsWho this might be right forLocally Advanced or Metastatic Non-Small Cell Lung Cancer AstraZeneca 454
Testing effectiveness (Phase 2)Study completedNCT02409368What this trial is testingAn Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCWho this might be right forNon-Small Cell Lung Cancer Bristol-Myers Squibb 812